MultiCell Technologies Inc (MCET)

[TPX]

MultiCell Technologies: MCT 465

Alternative Names: MCT-465
Latest Information Update: 04 Nov 2017

At a glance
Originator MultiCell Technologies Inc
Developer MultiCell Technologies Inc; University Health Network
Class Antivirals; RNA
Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; T lymphocyte stimulants; Toll-like receptor agonists
Orphan Drug Status No
New Molecular Entity Yes
Highest Development Phases

Preclinical Viral hepatitis
No development reported Cancer; Liver cancer
Discontinued Influenza virus infections
Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)
25 Aug 2014 Pharmacodynamics data from preclinical studies in Cancer and Viral hepatitis released by MultiCell Technologies

http://adisinsight.springer.com/drugs/800023642